


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app23.us.archive.org';v.server_ms=708;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Squamous cell carcinoma of the vulva. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712210627im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712210627im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712210627im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712210627im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712210627/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712210627im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712210627cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712210627js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712210627if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712210627/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712210627if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712210627/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712210627/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712210627/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712210627/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712210627/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712210627/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712210627/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712210627/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712210627/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712210627/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712210627/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712210627/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712210627/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712210627/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712210627/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712210627/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712210627/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712210627/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712210627/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712210627/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010268</li>
            <li>2011 Aug (revised 2013 Sep)
            </li>            
                                </ul>
        <div>
                <h1>Squamous cell carcinoma of the vulva.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712210627/https://www.guideline.gov/search?f_Guideline_Developer_String=CancerControl%20Alberta&amp;fLockTerm=CancerControl%2BAlberta">CancerControl Alberta</a></li>
                        <li>   
                                <a id="2278" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Alberta Provincial Gynecologic Oncology Team. Squamous cell carcinoma of the vulva. Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 10 p.&nbsp;(Clinical practice guideline; no. GYNE-006).&nbsp; [28 references]</td></tr></table>                    <p><a href="/web/20180712210627/https://www.guideline.gov/Home/Disclaimer?id=47850&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.albertahealthservices.ca%252fassets%252finfo%252fhp%252fcancer%252fif-hp-cancer-guide-gyne006-vulva.pdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210627im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Gynecologic Oncology Tumour Team. Squamous cell carcinoma of the vulva. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2011 Aug. 9 p. (Clinical practice guideline; no. GYNE-006). [28 references]</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
                        <li><a href="/web/20180712210627/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180712210627/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180712210627/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180712210627/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_ICD9CM_CUI=C1744618&amp;fLockTerm=Biopsy+of+vulva">Biopsy of vulva</a>
 (71.11), <a href="/web/20180712210627/https://www.guideline.gov/search?f_ICD9CM_CUI=C0278729&amp;fLockTerm=Carcinoma+in+situ%2c+vulva">Carcinoma in situ, vulva</a>
 (233.32), <a href="/web/20180712210627/https://www.guideline.gov/search?f_ICD9CM_CUI=C0375071&amp;fLockTerm=Malignant+neoplasm+of+vulva%2c+unspecified+site">Malignant neoplasm of vulva, unspecified site</a>
 (184.4), <a href="/web/20180712210627/https://www.guideline.gov/search?f_ICD9CM_CUI=C0193888&amp;fLockTerm=Radical+groin+dissection">Radical groin dissection</a>
 (40.54), <a href="/web/20180712210627/https://www.guideline.gov/search?f_ICD9CM_CUI=C0177252&amp;fLockTerm=Radical+vulvectomy">Radical vulvectomy</a>
 (71.5)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0003392&amp;fLockTerm=Antineoplastic+Agents">Antineoplastic Agents</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0003393&amp;fLockTerm=Antineoplastic+Combined+Chemotherapy+Protocols">Antineoplastic Combined Chemotherapy Protocols</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0005771&amp;fLockTerm=Blood+Cell+Count">Blood Cell Count</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0007137&amp;fLockTerm=Carcinoma%2c+Squamous+Cell">Carcinoma, Squamous Cell</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0085533&amp;fLockTerm=Chemotherapy%2c+Adjuvant">Chemotherapy, Adjuvant</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0013216&amp;fLockTerm=Drug+Therapy">Drug Therapy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0016360&amp;fLockTerm=Fluorouracil">Fluorouracil</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0038902&amp;fLockTerm=Gynecologic+Surgical+Procedures">Gynecologic Surgical Procedures</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0022662&amp;fLockTerm=Kidney+Function+Tests">Kidney Function Tests</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0023901&amp;fLockTerm=Liver+Function+Tests">Liver Function Tests</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0024203&amp;fLockTerm=Lymph+Node+Excision">Lymph Node Excision</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0025084&amp;fLockTerm=Medical+History+Taking">Medical History Taking</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0002475&amp;fLockTerm=Mitomycin">Mitomycin</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0030664&amp;fLockTerm=Pathology">Pathology</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0030679&amp;fLockTerm=Patient+Care+Team">Patient Care Team</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0032743&amp;fLockTerm=Positron-Emission+Tomography">Positron-Emission Tomography</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0033250&amp;fLockTerm=Proctoscopes">Proctoscopes</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0033251&amp;fLockTerm=Proctoscopy">Proctoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C1522449&amp;fLockTerm=Radiotherapy">Radiotherapy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0242939&amp;fLockTerm=Radiotherapy%2c+Adjuvant">Radiotherapy, Adjuvant</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0034928&amp;fLockTerm=Referral+and+Consultation">Referral and Consultation</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0183294&amp;fLockTerm=Sigmoidoscopes">Sigmoidoscopes</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0037075&amp;fLockTerm=Sigmoidoscopy">Sigmoidoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0936234&amp;fLockTerm=Tomography+Scanners%2c+X-Ray+Computed">Tomography Scanners, X-Ray Computed</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0040405&amp;fLockTerm=Tomography%2c+X-Ray+Computed">Tomography, X-Ray Computed</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0042995&amp;fLockTerm=Vulvar+Neoplasms">Vulvar Neoplasms</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MSH_CUI=C0195066&amp;fLockTerm=Vulvectomy">Vulvectomy</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0003392&amp;fLockTerm=Antineoplastic+Agents">Antineoplastic Agents</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C1744618&amp;fLockTerm=Biopsy+of+vulva">Biopsy of vulva</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0005771&amp;fLockTerm=blood+cell+count">blood cell count</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0392920&amp;fLockTerm=Chemotherapy+Regimen">Chemotherapy Regimen</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0280055&amp;fLockTerm=cisplatin%2ffluorouracil+protocol">cisplatin/fluorouracil protocol</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0936234&amp;fLockTerm=Computed+Tomography+Scanning+Systems">Computed Tomography Scanning Systems</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0016360&amp;fLockTerm=Fluorouracil">Fluorouracil</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C1522577&amp;fLockTerm=follow-up">follow-up</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0022662&amp;fLockTerm=Kidney+Function+Tests">Kidney Function Tests</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0023901&amp;fLockTerm=Liver+Function+Tests">Liver Function Tests</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0024203&amp;fLockTerm=Lymph+node+excision">Lymph node excision</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0375071&amp;fLockTerm=Malignant+neoplasm+of+vulva">Malignant neoplasm of vulva</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0002475&amp;fLockTerm=Mitomycin">Mitomycin</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0030664&amp;fLockTerm=Pathology">Pathology</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0919386&amp;fLockTerm=Pathology+procedure">Pathology procedure</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0013216&amp;fLockTerm=Pharmacotherapy">Pharmacotherapy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0039985&amp;fLockTerm=Plain+chest+X-ray">Plain chest X-ray</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0032743&amp;fLockTerm=Positron-Emission+Tomography">Positron-Emission Tomography</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0033251&amp;fLockTerm=Proctoscopy">Proctoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0302617&amp;fLockTerm=Radiographic-therapeutic+unit+device">Radiographic-therapeutic unit device</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0037075&amp;fLockTerm=Sigmoidoscopy+(procedure)">Sigmoidoscopy (procedure)</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0007137&amp;fLockTerm=Squamous+cell+carcinoma">Squamous cell carcinoma</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0278729&amp;fLockTerm=Stage+0+Vulvar+Carcinoma">Stage 0 Vulvar Carcinoma</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C1522449&amp;fLockTerm=Therapeutic+radiology+procedure">Therapeutic radiology procedure</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_MTH_CUI=C0040405&amp;fLockTerm=X-Ray+Computed+Tomography">X-Ray Computed Tomography</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0005558&amp;fLockTerm=biopsies">biopsies</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0008838&amp;fLockTerm=cisplatin">cisplatin</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0280055&amp;fLockTerm=cisplatin%2ffluorouracil">cisplatin/fluorouracil</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0040405&amp;fLockTerm=computed+tomography">computed tomography</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0010702&amp;fLockTerm=cystoscopy">cystoscopy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0016360&amp;fLockTerm=fluorouracil">fluorouracil</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0024203&amp;fLockTerm=lymphadenectomy">lymphadenectomy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0002475&amp;fLockTerm=mitomycin+C">mitomycin C</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C1522449&amp;fLockTerm=radiation+therapy">radiation therapy</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_PDQ_CUI=C0280856&amp;fLockTerm=squamous+cell+carcinoma+of+the+vulva">squamous cell carcinoma of the vulva</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003392&amp;fLockTerm=Antineoplastic+agent">Antineoplastic agent</a>
 (27867009), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003392&amp;fLockTerm=Antineoplastic+agent">Antineoplastic agent</a>
 (372688009), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0392920&amp;fLockTerm=Antineoplastic+chemotherapy+regimen">Antineoplastic chemotherapy regimen</a>
 (716872004), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
 (129314006), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005558&amp;fLockTerm=Biopsy">Biopsy</a>
 (86273004), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1744618&amp;fLockTerm=Biopsy+of+vulva">Biopsy of vulva</a>
 (274942001), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005771&amp;fLockTerm=Blood+cell+count">Blood cell count</a>
 (88308000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0278729&amp;fLockTerm=Carcinoma+in+situ+of+vulva">Carcinoma in situ of vulva</a>
 (92802003), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
 (387318005), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
 (57066004), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040405&amp;fLockTerm=Computerized+axial+tomography">Computerized axial tomography</a>
 (77477000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
 (24139008), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0013216&amp;fLockTerm=Drug+therapy">Drug therapy</a>
 (416608005), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0558588&amp;fLockTerm=Examination+under+anesthesia">Examination under anesthesia</a>
 (274392008), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024203&amp;fLockTerm=Excision+of+lymph+node">Excision of lymph node</a>
 (234253006), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024203&amp;fLockTerm=Excision+of+lymph+node">Excision of lymph node</a>
 (58347006), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0850169&amp;fLockTerm=Excision+of+malignant+neoplasm">Excision of malignant neoplasm</a>
 (370611004), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016360&amp;fLockTerm=Fluorouracil">Fluorouracil</a>
 (3127006), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0016360&amp;fLockTerm=Fluorouracil">Fluorouracil</a>
 (387172005), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0023901&amp;fLockTerm=Liver+function+tests+-+general">Liver function tests - general</a>
 (26958001), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0023901&amp;fLockTerm=Liver+function+tests+-+general">Liver function tests - general</a>
 (271552009), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0375071&amp;fLockTerm=Malignant+tumor+of+vulva">Malignant tumor of vulva</a>
 (363367000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002475&amp;fLockTerm=Mitomycin">Mitomycin</a>
 (387331000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0002475&amp;fLockTerm=Mitomycin">Mitomycin</a>
 (59240002), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042995&amp;fLockTerm=Neoplasm+of+vulva">Neoplasm of vulva</a>
 (126922007), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0038902&amp;fLockTerm=Operation+on+female+genital+organs">Operation on female genital organs</a>
 (12658000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030664&amp;fLockTerm=Pathology">Pathology</a>
 (394595002), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0039985&amp;fLockTerm=Plain+chest+X-ray">Plain chest X-ray</a>
 (399208008), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032743&amp;fLockTerm=Positron+emission+tomography">Positron emission tomography</a>
 (363678002), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0032743&amp;fLockTerm=Positron+emission+tomography">Positron emission tomography</a>
 (82918005), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0182349&amp;fLockTerm=Positron+emission+tomography+unit">Positron emission tomography unit</a>
 (39821008), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0182349&amp;fLockTerm=Positron+emission+tomography+unit">Positron emission tomography unit</a>
 (462323006), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033250&amp;fLockTerm=Proctoscope">Proctoscope</a>
 (47942000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033251&amp;fLockTerm=Proctoscopy">Proctoscopy</a>
 (42238002), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1522449&amp;fLockTerm=Radiation+oncology+AND%2fOR+radiotherapy">Radiation oncology AND/OR radiotherapy</a>
 (108290001), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1522449&amp;fLockTerm=Radiation+oncology+AND%2fOR+radiotherapy">Radiation oncology AND/OR radiotherapy</a>
 (53438000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0193888&amp;fLockTerm=Radical+dissection+of+groin">Radical dissection of groin</a>
 (5998008), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0177252&amp;fLockTerm=Radical+vulvectomy">Radical vulvectomy</a>
 (287966005), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0302617&amp;fLockTerm=Radiographic-therapeutic+unit">Radiographic-therapeutic unit</a>
 (10850003), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0420395&amp;fLockTerm=Referral+to+oncologist">Referral to oncologist</a>
 (183529009), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0022662&amp;fLockTerm=Renal+function+study">Renal function study</a>
 (44277000), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0183294&amp;fLockTerm=Sigmoidoscope">Sigmoidoscope</a>
 (310199004), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0037075&amp;fLockTerm=Sigmoidoscopy">Sigmoidoscopy</a>
 (24420007), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007137&amp;fLockTerm=Squamous+cell+carcinoma">Squamous cell carcinoma</a>
 (28899001), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007137&amp;fLockTerm=Squamous+cell+carcinoma">Squamous cell carcinoma</a>
 (402815007), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0280856&amp;fLockTerm=Squamous+cell+carcinoma+of+vulva">Squamous cell carcinoma of vulva</a>
 (254895003), <a href="/web/20180712210627/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0195066&amp;fLockTerm=Vulvectomy">Vulvectomy</a>
 (36901005)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SPN</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_SPN_CUI=C0033250&amp;fLockTerm=PROCTOSCOPE">PROCTOSCOPE</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_SPN_CUI=C0182349&amp;fLockTerm=SYSTEM%2c+TOMOGRAPHY%2c+COMPUTED%2c+EMISSION">SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION</a>
, <a href="/web/20180712210627/https://www.guideline.gov/search?f_SPN_CUI=C0936234&amp;fLockTerm=SYSTEM%2c+X-RAY%2c+TOMOGRAPHY%2c+COMPUTED">SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0179314&amp;fLockTerm=Procedure+Kit%2fTrays%2c+Biopsy">Procedure Kit/Trays, Biopsy</a>
 (10-401), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0033250&amp;fLockTerm=Proctoscopes">Proctoscopes</a>
 (13-126), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0182606&amp;fLockTerm=Radiographic+Units%2c+Chest">Radiographic Units, Chest</a>
 (10-822), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0302617&amp;fLockTerm=Radiotherapy+Systems">Radiotherapy Systems</a>
 (13-279), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0936234&amp;fLockTerm=Scanning+Systems%2c+Computed+Tomography">Scanning Systems, Computed Tomography</a>
 (13-469), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0182349&amp;fLockTerm=Scanning+Systems%2c+Positron+Emission+Tomography">Scanning Systems, Positron Emission Tomography</a>
 (16-375), <a href="/web/20180712210627/https://www.guideline.gov/search?f_UMD_CUI=C0183294&amp;fLockTerm=Sigmoidoscopes">Sigmoidoscopes</a>
 (13-594)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/downloadcontent/ngc-10268?contentType=pdf" class="pdf">.PDF 95.4 kb</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/downloadcontent/ngc-10268?contentType=word" class="word">Word Document 287.1 kb</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/downloadcontent/ngc-10268?contentType=xml" class="xml">.XML 37.7 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210627/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210627/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210627/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712210627/mailto:/?Subject=AHRQ: Squamous cell carcinoma of the vulva.&amp;body=https://www.guideline.gov/summaries/summary/47850/squamous-cell-carcinoma-of-the-vulva" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Squamous cell carcinoma of the vulva. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Sep 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850">RefWorks</a></li>
                            <li><a href="/web/20180712210627/https://www.guideline.gov/summaries/citedownload/47850?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47850" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Staging is based on the F&eacute;d&eacute;ration Internationale de Gynecologie et d'Obst&eacute;trique (FIGO) classification system, which was updated in 2010. A detailed description of this staging system can be found in the Appendix in the original guideline document.</p>
<p><strong>Pre-operative Investigations</strong></p>
<p>Investigations should include:</p>
<ul style="list-style-type: disc;">
    <li>History and clinical exam, biopsy </li>
    <li>Chest x-ray </li>
    <li>Blood work (complete blood count [CBC], liver function tests [LFT], renal function studies) </li>
</ul>
<p>The following investigations could be considered, as clinically indicated:</p>
<ul style="list-style-type: disc;">
    <li>Computed tomography (CT) chest/abdomen/pelvis </li>
    <li>Examination under anesthesia (EUA) cystoscopy +/- sigmoidoscopy/proctoscopy, as clinically indicated </li>
</ul>
<p><strong>Primary Treatment</strong></p>
<ul style="list-style-type: disc;">
    <li>Patients with a locally advanced primary or nodal disease should be referred for multidisciplinary clinical evaluation. </li>
    <li>An expert pathology review should be performed by a pathologist with experience in gynecologic pathology. </li>
    <li>Surgical management of the primary tumour and the lymph nodes depends on the size and location of the primary tumour (see the table below) (GOG 173 Study, unpublished results). </li>
    <li>Radical radiotherapy could be considered as an alternative to surgery in patients deemed unsuitable for surgery because of site or extent of disease, or where preservation of the clitoris or anal sphincter is desired. </li>
    <li>In patients with tumours &gt;2 cm, chemoradiotherapy could also be considered as an alternative to surgery in patients deemed unsuitable for surgery because of site or extent of disease, or where preservation of the clitoris or anal sphincter is desired. </li>
</ul>
<p><strong>Table. Surgical Management of Squamous Cell Carcinoma of the Vulva</strong></p>
<table border="1" cellspacing="1" cellpadding="3" summary="Table: Surgical Management of Squamous Cell Carcinoma of the Vulva">
    <thead>
        <tr>
            <th class="Center" valign="top">Tumour Size (cm)</th>
            <th class="Center" valign="top">Invasion (mm)</th>
            <th class="Center" valign="top">Location</th>
            <th class="Center" valign="top">Recommended Surgery</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td class="Center" valign="top">&lt;2</td>
            <td class="Center" valign="top">&lt;1</td>
            <td class="Center" valign="top">Lateral or central</td>
            <td valign="top">Consider wide local excision</td>
        </tr>
        <tr>
            <td class="Center" valign="top">&lt;2</td>
            <td class="Center" valign="top">&lt;5</td>
            <td class="Center" valign="top">Lateral</td>
            <td valign="top">Consider radical local excision with unilateral lymphadenectomy</td>
        </tr>
        <tr>
            <td class="Center" valign="top">&lt;2</td>
            <td class="Center" valign="top">&lt;5</td>
            <td class="Center" valign="top">Central*</td>
            <td valign="top">Consider radical local excision with bilateral lymphadenectomy</td>
        </tr>
        <tr>
            <td class="Center" valign="top">&lt;2</td>
            <td class="Center" valign="top">&gt;5</td>
            <td class="Center" valign="top">Lateral</td>
            <td valign="top">Consider radical vulvectomy with unilateral or bilateral lymphadenectomy</td>
        </tr>
        <tr>
            <td class="Center" valign="top">&lt;2</td>
            <td class="Center" valign="top">&gt;5</td>
            <td class="Center" valign="top">Central*</td>
            <td valign="top">Consider radical vulvectomy with bilateral lymphadenectomy; separate groin incisions and unilateral lymphadenectomy for select early lesions may reduce morbidity</td>
        </tr>
        <tr>
            <td class="Center" valign="top">&gt;2</td>
            <td class="Center" valign="top">Any</td>
            <td class="Center" valign="top">Lateral or central</td>
            <td valign="top">Consider radical vulvectomy with bilateral lymphadenectomy; separate groin incisions and unilateral lymphadenectomy for select early lesions may reduce morbidity</td>
        </tr>
    </tbody>
</table>
<p class="Note">*Up to 1 cm from midline</p>
<ul style="list-style-type: disc;">
    <li>Chemoradiotherapy is recommended, as primary definitive treatment in patients with extension to adjacent perineal structures and/or positive nodes.
    <ul style="list-style-type: disc;">
        <li>Chemotherapy options include: fluorouracil (5-FU) alone, 5-FU plus cisplatin, or 5-FU plus mitomycin-C, or cisplatin alone, based on patient factors (i.e., renal insufficiency, ototoxicity, deafness). </li>
        <li>Radiotherapy volume and dose will be individualized by the radiation oncologist. </li>
    </ul>
    </li>
</ul>
<p><strong>Adjuvant Treatment</strong></p>
<ul style="list-style-type: disc;">
    <li><strong>Stage IA</strong>: the preferred treatment for stage IA disease is wide local excision (WLE) only. </li>
    <li><strong>Stage IB</strong>: post-operative radiotherapy could be considered for close positive margins, at the discretion of the radiation oncologist. </li>
    <li><strong>Stage II</strong>: post-operative radiotherapy could be considered for close positive margins, at the discretion of the radiation oncologist. </li>
    <li><strong>Stage III</strong>:
    <ul style="list-style-type: disc;">
        <li>Patients who are pathologically node positive should be referred to radiation oncology for clinical evaluation. </li>
        <li>For patients with one lymph node metastasis (&lt;5 mm and no extracapsular extension) post-operative radiotherapy is not recommended. </li>
        <li>For patients with two or more lymph node metastases (&ge;5 mm) or three or more lymph node metastases (&lt;5 mm), and for patients with positive nodes with extracapsular spread, post-operative radiotherapy is recommended. </li>
        <li>If findings are positive for a unilateral groin node dissection for a small (&lt;2 cm) lateral lesion, dissection of the contralateral groin is recommended. </li>
        <li>Adjuvant local radiotherapy should also be considered for close margins. </li>
    </ul>
    </li>
    <li><strong>Stage IVA and IVB</strong>: for patients with invasion to regional (2/3 upper) structures or distant sites, with or without positive nodes, post-operative radiotherapy is recommended.
    <ul style="list-style-type: disc;">
        <li>Adjuvant local radiotherapy should also be considered for close margins. </li>
    </ul>
    </li>
</ul>
<p><strong>Follow-up and Surveillance</strong></p>
<p>Patients treated with chemoradiotherapy as primary definitive treatment should be seen as follows:</p>
<ul style="list-style-type: disc;">
    <li>Clinical exam at 4 to 6 weeks </li>
    <li>Other tests as clinically indicated (i.e., suspicious clinical exam):
    <ul style="list-style-type: disc;">
        <li>Imaging with CT or positron emission tomography (PET)-CT, as indicated </li>
        <li>EUA with biopsy, post-treatment, if outpatient exam is not possible </li>
    </ul>
    </li>
    <li>If imaging or biopsy is positive, consider salvage surgery </li>
</ul>
<p>Long-term follow-up of all patients should include:</p>
<ul style="list-style-type: disc;">
    <li>Year 1: every 3 months, or as clinically indicated </li>
    <li>Year 2: every 4 months, or as clinically indicated </li>
    <li>Years 3&ndash;5: every six months, or as clinically indicated </li>
</ul></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>The following algorithms are provided on the <a href="/web/20180712210627/https://www.guideline.gov/Home/Disclaimer?id=47850&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-gyne006-algorithm-vulva.pdf" title="Alberta Health Services Web site">Alberta Health Services Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210627im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>:</p>
<ul style="list-style-type: disc;">
    <li>Algorithm for the diagnosis &amp; referral of squamous cell carcinoma of the vulva (GYNE-006) </li>
    <li>Algorithm for the management of early stage squamous cell carcinoma of the vulva (GYNE-006) </li>
    <li>Algorithm for the management of advanced stage squamous cell carcinoma of the vulva (GYNE-006) </li>
</ul></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Squamous cell carcinoma of the vulva</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Family Practice</p>
                    <p>Obstetrics and Gynecology</p>
                    <p>Oncology</p>
                    <p>Pathology</p>
                    <p>Radiation Oncology</p>
                    <p>Surgery</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Clinical Laboratory Personnel</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To recommend options for the management of vulvar cancer, based on the best evidence available</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Adults over the age of 18 years with squamous cell carcinoma of the vulva</p>
<p class="Note"><strong>Note</strong>: This guideline does not address patients with other vulvar cancer histologies, including adenocarcinoma, basal cell carcinoma, and melanoma.</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Evaluation (Pre-operative Investigations)</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>History and clinical exam, biopsy </li>
    <li>Chest x-ray </li>
    <li>Blood work (complete blood count [CBC], liver function tests [LFT], renal function studies) </li>
    <li>Computed tomography (CT) chest/abdomen/pelvis </li>
    <li>Positron emission tomography (PET)-CT </li>
    <li>Examination under anesthesia (EUA) cystoscopy +/- sigmoidoscopy/proctoscopy, as clinically indicated </li>
</ol>
<p><strong>Treatment/Management</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Referral for multidisciplinary clinical evaluation </li>
    <li>Expert pathology review </li>
    <li>Surgical management based on tumour size, invasion, and location
    <ul style="list-style-type: disc;">
        <li>Wide local excision (WLE) </li>
        <li>Radical local excision with unilateral or bilateral lymphadenectomy </li>
        <li>Radical vulvectomy with unilateral or bilateral lymphadenectomy </li>
    </ul>
    </li>
    <li>Radical radiotherapy as an alternative to surgery </li>
    <li>Chemoradiotherapy </li>
    <li>Chemotherapy (fluorouracil [5-FU] alone, 5-FU plus cisplatin, 5-FU plus mitomycin-C, or cisplatin alone) </li>
    <li>Adjuvant treatment based on disease stage (e.g., post-operative radiotherapy, dissection of the contralateral groin) </li>
    <li>Follow-up and surveillance </li>
</ol></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Cancer-related death rate </li>
    <li>Relative risk of disease progression </li>
    <li>Progression-free interval </li>
    <li>Overall and disease-free survival </li>
    <li>Local control </li>
    <li>Recurrence rate </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Research Questions</strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (Patient or Population, Intervention, Comparisons, Outcomes).</p>
<p><strong>Guideline Questions</strong></p>
<ul style="list-style-type: disc;">
    <li>What is the role of post-operative, adjuvant radiotherapy in early stage vulvar cancer? </li>
    <li>What is the role of definitive radiotherapy or chemoradiotherapy in advanced stage vulvar cancer? </li>
    <li>What is the role of sentinel lymph node biopsy in patients with clinically negative nodes, with tumours &lt;2 cm? </li>
    <li>What is the role of surgery in patients with metastasis to the inguinofemoral nodes? </li>
    <li>What is the most appropriate follow-up schedule for advanced stage patients treated with chemoradiotherapy only? </li>
</ul>
<p><strong>Search Strategy</strong></p>
<p>Entries to the Medline and EMBASE databases and clinical practice guideline databases (e.g., National Guideline Clearinghouse, CancerView, etc.) were searched for evidence relevant to this topic. Search terms included: neoplasm AND vulva or vulvar, with limits of studies in humans, clinical trials, and studies in English. Studies that did not report response rates or survival rates were further excluded.</p>
<p>The initial search in 2011 returned a total of 55 relevant studies, which included clinical trials, retrospective studies, and case studies. The search was repeated in 2013 and returned a total of three relevant citations.</p>
<p>Existing guidelines considered for this review include the following: Society of Obstetricians and Gynaecologists of Canada guidelines (2006), National Cancer Institute guidelines (2009), the Royal College of Obstetricians and Gynaecologists guidelines (2006), and the BC Cancer Agency (BCCA) guidelines (2000).</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>The initial search in 2011 returned a total of 55 relevant studies, which included clinical trials, retrospective studies, and case studies. The search was repeated in 2013 and returned a total of 3 relevant citations.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Not stated</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Gynecologic Oncology Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the "Availability of Companion Documents" field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic will be assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href="/web/20180712210627/https://www.guideline.gov/Home/Disclaimer?id=47850&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.agreetrust.org" title="AGREE Web site">http://www.agreetrust.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210627im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulate the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the Guideline Utilization Resource Unit Handbook (see the "Availability of Companion Documents" field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p>
<p>An effort was made to either adapt or adopt the most appropriate guidelines from other sources so that work wasn't duplicated. An evidence based perspective was used to draft proposals. Where evidence was weak, recommendations were based on group consensus.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>This guideline was reviewed and endorsed by the Alberta Provincial Gynecologic Oncology Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management (KM) Specialist and the working group members, it will be sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of evidence supporting the recommendations is not specifically stated.</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate management of squamous cell carcinoma of the vulva</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>For advanced vulvar cancer, neoadjuvant radiation with or without chemotherapy followed by radical surgery should be considered the best option for management. However, this may be associated with more morbidity than either radiotherapy or chemotherapy alone with surgery.</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Gynecologic Oncology Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services website. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Clinical Algorithm</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Alberta Provincial Gynecologic Oncology Team. Squamous cell carcinoma of the vulva. Edmonton (Alberta): CancerControl Alberta; 2013 Sep. 10 p.&nbsp;(Clinical practice guideline; no. GYNE-006).&nbsp; [28 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2011 Aug (revised 2013 Sep)</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>CancerControl Alberta - State/Local Government Agency [Non-U.S.]</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>CancerControl Alberta</p>
<p>There was no direct industry involvement in the development or dissemination of this guideline.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Alberta Provincial Gynecologic Oncology Tumour Team</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p>Members of the Alberta Provincial Gynecologic Oncology Tumour Team include gynecologic oncologists, radiation oncologists, medical oncologists, pathologists, nurses, and pharmacists.</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Participation of members of the Alberta Provincial Gynecologic Oncology Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Gynecologic Oncology Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p>
<p>This guideline updates a previous version: Alberta Provincial Gynecologic Oncology Tumour Team. Squamous cell carcinoma of the vulva. Edmonton (Alberta): Alberta Health Services, Cancer Care; 2011 Aug. 9 p. (Clinical practice guideline; no. GYNE-006). [28 references]</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180712210627/https://www.guideline.gov/Home/Disclaimer?id=47850&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-gyne006-vulva.pdf" title="Alberta Health Services Web site">Alberta Health Services Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210627im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on December 19, 2012. The information was verified by the guideline developer on February 1, 2013. This summary was updated by ECRI Institute on April 28, 2014. The updated information was verified by the guideline developer on June 6, 2014. This summary was updated by ECRI Institute on February 15, 2017 following the U.S. Food and Drug Administration advisory on general anesthetic and sedation drugs.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712210627/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712210627/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712210627/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210627/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210627/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210627/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210627/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210627/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712210627/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712210627/https://www.guideline.gov/disclaimer?id=47850&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712210627/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712210627/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712210627/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712210627/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712210627/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712210627/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712210627/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712210627/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712210627/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712210627/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712210627/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712210627/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712210627/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712210627im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712210627/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712210627/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712210627js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712210627js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 21:06:27 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:46:00 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 558.168 (3)
  esindex: 0.015
  captures_list: 579.771
  CDXLines.iter: 16.258 (3)
  PetaboxLoader3.datanode: 107.404 (4)
  exclusion.robots: 0.289
  exclusion.robots.policy: 0.27
  RedisCDXSource: 0.679
  PetaboxLoader3.resolve: 535.821 (4)
  load_resource: 102.664
-->